References
- Aksentijevich I., Nowak M., Mallah M., Chae J., Watford W., Hofmann S., et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID). Arthritis & Rheumatism, 46: 3340–3348.
- Campbell A., Clifton F. 1950. Adult toxoplasmosis in one family. Brain, 73: 281–290.
- Feldmann J., Prieur A., Quartier P., Berquin P., Certain S., Cortis E., et al. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. The American Journal of Human Genetics, 71: 198–203.
- Frenkel J., Wulffraat N., Kuis W. 2004. Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis & Rheumatism, 50: 3738–3739.
- Goldbach-Mansky R., Dailey N., Canna S., Gelabert A., Jones J., Rubin B., et al. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. The New England Journal of Medicine, 355: 581–592.
- Goldfinger S. 2009. The inherited autoinflammatory syndrome: a decade of discovery. Transactions of the American Clinical and Climatological Association, 120: 413–418.
- Hawkins P., Lachmann H., Aganna E., Mcdermott M. 2004. Spectrum of clinical features in Muckle–Wells syndrome and response to anakinra. Arthritis & Rheumatism, 50: 607–612.
- Hedrich C., Fiebig B., Sallmann S., Bruck N., Hahn G., Roesler J., et al. 2008. Good response to IL-1beta blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies. Scandinavian Journal of Rheumatology, 37: 385–389.
- Hill S., Namde M., Dwyer A., Poznanski A., Canna S., Goldbach-Mansky R. 2007. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatric Radiology, 37: 145–152.
- Klein A., Horneff G. 2010. Improvement of sensoneurinal hearing loss in a patient with Muckle–Wells syndrome treated with anakinra. Klinische Padiatrie, 222(4): 266–268.
- Lovell D., Bowyer S., Solinger A. 2005. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis & Rheumatism, 52: 1283–1286.
- Prieur A. 2001. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clinical and Experimental Rheumatology, 19: 103–106.
- Prieur A., Griscelli C., Lampert F., Truckenbrodt H., Guggenheim M., Lovell D., et al. 1987. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scandinavian Journal of Rheumatology – Supplement, 66: 57–68.
- Rynne M., Maclean C., Bybee A., Mcdermott M., Emery P. 2006. Hearing improvement in a patient with variant Muckle–Wells syndrome in response to interleukin 1 receptor antagonism. Annals of the Rheumatic Diseases, 65: 533–534.
- Stojanov S., Kastner D. 2005. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Current Opinion in Rheumatology, 17: 586–599.
- Teoh S., Sharma S., Hogan A., Lee R., Ramanan A., Dick A. 2007. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. British Journal of Ophthalmology, 91: 263–264.